ArticleFrontiers in immunology2026
FOXA1-driven transcription and TRIM9-mediated ubiquitination of LCN2 modulate ferroptosis in experimental sepsis-induced acute lung injury.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis-induced acute lung injury (ALI) remains a devastating complication of sepsis, marked by uncontrolled pulmonary inflammation, alveolar-capillary barrier disruption, and high mortality. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, is implicated in sepsis-related organ dysfunction. Moreover, a ferroptosis-related gene, Lipocalin 2 (LCN2), has been reported as a potential biomarker for sepsis-induced organ damage. However, the role and mechanism of LCN2 in sepsis-triggered ALI are still unclear. Methods: Transcriptomic data from GSE32707 were integrated for differential expression and WGCNA analysis. One overlapping gene was identified using key modules from WGCNA and ferroptosis-related genes from GeneCards database. LCN2 mRNA level was determined using real-time quantitative polymerase chain reaction (RT-qPCR). LCN2, Forkhead box protein A1 (FOXA1), tripartite motif-containing protein 9 (TRIM9), GPX4, SLC7A11, Occludin, and ZO-1 protein levels were detected using western blot. An Results: LCN2 was identified by intersecting WGCNA-derived MEsalmom and MEmidnightblue modules and ferroptosis-related genes from GeneCards database. LCN2 expression was upregulated in sepsis patients and LPS-treated HPMECs. LPS-induced HPMEC proliferation inhibition, and apoptosis, inflammatory response and ferroptosis promotion were partly abolished by LCN2 silencing. Mechanistically, FOXA1 activated LCN2 transcription by binding to its promoter region. TRIM9 promoted K48-linked polyubiquitination and subsequent degradation of LCN2. In CLP rats, LCN2 knockdown reduced lung injury and decreases pro-inflammatory cytokines, with accompanying changes in ferroptosis-related markers. Conclusion: This study demonstrates that FOXA1 transcriptionally activates LCN2, while TRIM9 promotes K48-linked ubiquitination and degradation of LCN2, together forming a dual-level regulatory mechanism that modulates ferroptosis and inflammation in LPS-treated HPMECs. Moreover, LCN2 knockdown alleviated lung injury with accompanying changes in ferroptosis-related markers in the CLP rat model, supporting the relevance of this axis
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.